新型TLR4激动剂优化RG1-VLP疫苗在小鼠中的免疫效果
该研究在BALB/c小鼠中比较了新型细菌酶组合化学(BECC)来源的TLR4激动剂与氢氧化铝佐剂对RG1-VLP(病毒样颗粒)疫苗的免疫增强作用。结果显示,含BECC分子佐剂可提高针对HPV16-L1和L2 RG1表位的抗体应答幅度,并增强对HPV16的中和滴度及对HPV18、HPV39假病毒的中和交叉反应。BECC/Alhydrogel佐剂两剂接种即可达到或超过单用Alhydrogel三剂的效果,并允许抗原剂量减少75%而保持应答幅度。
要点
- BECC/TLR4激动剂佐剂可增强RG1-VLP疫苗的抗体应答和交叉中和能力。
- BECC/Alhydrogel两剂接种的抗体水平相当于或高于Alhydrogel三剂。
- BECC/Alhydrogel佐剂可实现抗原剂量减少75%而保持应答幅度。
核心结论
- BECC来源的TLR4激动剂与Alhydrogel联用可增强RG1-VLP疫苗的免疫原性,加速免疫应答,并允许减少接种剂次和抗原剂量。
研究设计与样本
- 在BALB/c小鼠中比较含新型BECC来源TLR4激动剂与Alhydrogel的佐剂配方对RG1-VLP疫苗的免疫效果。
主要发现
- 含BECC分子时,针对HPV16-L1和L2 RG1表位的抗体应答幅度较单用Alhydrogel持续改善。
- 含BECC激动剂时,对HPV16的中和滴度及对HPV18和HPV39假病毒的中和交叉反应增强。
- BECC/Alhydrogel两剂接种后L1和L2特异性抗体水平相当于或高于单用Alhydrogel三剂接种。
- BECC/Alhydrogel佐剂允许抗原剂量减少75%而仍保持与全剂量VLP加Alhydrogel相当的应答幅度。
临床怎么用
- 佐剂优化可缩短HPV VLP疫苗的免疫程序并降低抗原用量。
- 该策略可能有助于降低VLP疫苗的生产成本并建立更持久体液免疫。
局限性
- 研究仅在小鼠中进行,尚未在人体验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Current human papilloma virus (HPV) vaccines provide substantial protection against the most common HPV types responsible for oral and anogenital cancers, but many circulating cancer-causing types remain that lack vaccine coverage. The novel RG1-VLP (virus-like particle) vaccine candidate utilizes the HPV16-L1 subunit as a backbone to display an inserted HPV16-L2 17-36 a.a. "RG1" epitope; the L2 RG1 epitope is conserved across many HPV types and the generation of cross-neutralizing antibodies (Abs) against which has been demonstrated. In an effort to heighten the immunogenicity of the RG1-VLP vaccine, we compared in BALB/c mice adjuvant formulations consisting of novel bacterial enzymatic combinatorial chemistry (BECC)-derived toll-like receptor 4 (TLR4) agonists and the aluminum hydroxide adjuvant Alhydrogel. In the presence of BECC molecules, consistent improvements in the magnitude of Ab responses to both HPV16-L1 and the L2 RG1 epitope were observed compared to Alhydrogel alone. Furthermore, neutralizing titers to HPV16 as well as cross-neutralization of pseudovirion (PsV) types HPV18 and HPV39 were augmented in the presence of BECC agonists as well. Levels of L1 and L2-specific Abs were achieved after two vaccinations with BECC/Alhydrogel adjuvant that were equivalent to or greater than levels achieved with 3 vaccinations with Alhydrogel alone, indicating that the presence of BECC molecules resulted in accelerated immune responses that could allow for a decreased dose schedule for VLP-based HPV vaccines. In addition, dose-sparing studies indicated that adjuvantation with BECC/Alhydrogel allowed for a 75% reduction in antigen dose while still retaining equivalent magnitudes of responses to the full VLP dose with Alhydrogel. These data suggest that adjuvant optimization of HPV VLP-based vaccines can lead to rapid immunity requiring fewer boosts, dose-sparing of VLPs expensive to produce, and the establishment of a longer-lasting humoral immunity.
引用
- Zacharia A, Harberts E, Valencia SM, et al. Optimization of RG1-VLP vaccine performance in mice with novel TLR4 agonists. Vaccine. 2020. PMID: 33309485. doi:10.1016/j.vaccine.2020.11.066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。